Revolution Medicines is currently developing a drug aimed at treating pancreatic cancer, which has not yet been approved by regulatory authorities.
As anticipation builds around this drug, conversations have begun to explore how and when its use might be broadened beyond its initial indications.
This early interest in potential expansion reflects the ongoing challenges and opportunities in the treatment landscape for pancreatic cancer.